Navigation Links
Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
Date:9/5/2012

option."

"Sym004 further strengthens our early development pipeline by adding a product that is thought to act via a proposed synergistic mechanism of action not previously studied, but more specifically, it has the potential to become a key asset complementing our already highly successful Erbitux franchise," commented Dr. Susan Jane Herbert, Head of Global Business Development and Strategy for Merck Serono. "This collaboration once again reflects our strong commitment to fighting cancer and to providing new treatment options to patients."

Sym004 is comprised of two antibodies that are not only designed to block ligand binding, receptor activation and downstream signaling but are also thought to elicit removal of the EGFR receptors from the cancer cell surface by inducing EGFR internalization and degradation.[1]

As of July 2012, 88 patients have been treated with Sym004 in clinical trials. The adverse events from the preliminary clinical data include diarrhea, skin rash, mucosal inflammation, nausea, infusion-related reaction and hypomagnesemia. Exposure data from the patients, after weekly repeated infusions, do not indicate an anti-drug antibody response.

References

1. Pedersen MW, et al. Cancer Res 2010;70:588-97.

Conference Call

Symphogen will host a conference call today (Thursday 6 September 2012) to discuss the announcement at 11:30 CET/ 10:30 BST.

Kirsten Drejer, Symphogen's Chief Executive Officer, will host the call to discuss the licence agreement with Merck KGaA for Sym004, followed by a Q&A session. The call will be conducted in English.  Please use the following dial-in details:

Denmark: 327-276-25

International: +44(0)1452-555-566

Please quote the following Conference ID: 28172177

An accompanying presentation will be released on Symphogen's website and available for download just before the start of the call and can be
'/>"/>

SOURCE Symphogen
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
2. USPTO Grants Butamax a Further KARI Enzyme Patent
3. Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
4. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
5. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
6. NSF CAREER grants support ocean energy, microforming, computer planning
7. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
8. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
9. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
10. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
11. MO BIO Laboratories, Inc. Becomes Exclusive Sponsor Of Natures Human Microbiota Special
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... TX (PRWEB) June 19, 2013 Applied ... application report that details the measurement of sulfur in ... NEX QC+ high resolution benchtop EDXRF analyzer . The ... standard test method ISO 13032. This International Standard ... for the determination of sulfur content in automotive gasoline. ...
(Date:6/19/2013)... MN (PRWEB) June 19, 2013 Express ... abuse tests, today announced that it has received Class ... market and sell its DrugCheck® NxStep Onsite Drug ... use of the rapid screening device in near-patient settings, ... Drug Screen Cup received Health Canada Class III approval ...
(Date:6/18/2013)... Clara, CA (PRWEB) June 18, 2013 ... to standard size SEMs but have limited performance and ... lower resolution. Full size SEMs would normally provide better ... more knowledge to operate and have a higher cost ... address the gap between these two types of ...
(Date:6/18/2013)... June 18, 2013 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its preliminary unaudited financial results for the ... ended March 31, 2013. Fourth Quarter ... fourth quarter of fiscal 2013 increased by 33.3% to ...
Breaking Biology Technology:Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13
... power they use. The more power they use, the hotter ... overheat. It doesn,t take a rocket scientist to understand what ... of electronics, thermal control is always one of the limiting ... to help cool down electronic components. However, Jeffrey ...
... BioStorage Technologies, the premier global provider of ... has opened its new state-of-the-art biorepository facility in ... company,s strategic growth plan, and represents a 4.6MM ... near the second largest FedEx hub in the ...
... 2011 Reportlinker.com announces that a new ... catalogue: Future Directions in ... Big Pharma has begun ... Pfizer and Novartis in 2009, and Cephalon ...
Cached Biology Technology:NASA is making hot, way cool 2NASA is making hot, way cool 3BioStorage Technologies Expands U.S. Operations with Opening of New Biorepository Facility 2BioStorage Technologies Expands U.S. Operations with Opening of New Biorepository Facility 3Reportlinker Adds Future Directions in Regenerative Medicine 2Reportlinker Adds Future Directions in Regenerative Medicine 3Reportlinker Adds Future Directions in Regenerative Medicine 4Reportlinker Adds Future Directions in Regenerative Medicine 5Reportlinker Adds Future Directions in Regenerative Medicine 6
(Date:6/18/2013)... Bethesda, MD, June 18, 2013: The Association for Molecular ... Federation of American Societies for Experimental Biology (FASEB) on ... for membership on June 3, 2013. , The ... individuals and share a common vision for the advancement ... "Basic biomedical and translational research is more important now ...
(Date:6/18/2013)... Adelaide shows that weight gain and increased head size in ... higher IQ at early school age. , The study was led ... more than 13,800 children who were born full-term. , The results, ... babies who put on 40% of their birthweight in the first ... they were six years of age, compared with babies who only ...
(Date:6/17/2013)... eat their food may turn out to be just as ... out of St. Michael,s Hospital. , The study, led ... association between poor eating habits in kids ages three ... cholesterol, putting them at risk for cardiovascular disease later ... Canadian Medical Association Journal today. , "We know ...
Breaking Biology News(10 mins):IQ link to baby's weight gain in first month 2Poor eating behaviors may put preschoolers at risk for later health problems 2
... are killing head corals and adding stress to Caribbean ... from global climate change, coral diseases, hurricanes, pollution, and ... will take the pressure off the other corals, according ... PLoS ONE . The small, belligerently territorial, ...
... More than two million miles of the ... is nearing the end of its useful ... do not attract much attention because of ... associate professor of civil and environmental engineering ...
... attacks are most likely to occur on Sunday, in less ... involve surfers wearing black and white bathing suits, a first ... Researchers analyzed statistics from shark attacks that occurred in ... World," between 1956 and 2008. They also spent a year ...
Cached Biology News:Distressed damsels stress coral reefs 2Efforts underway at Virginia Tech to address deterioration of nation's water pipes 2Case study analyzes why, where and when of leading shark attack site 2Case study analyzes why, where and when of leading shark attack site 3
... Goat polyclonal to PAX3 This ... box (PAX) family of transcription factors. Members ... paired box domain and a paired-type homeodomain. ... development. Mutations in paired box gene 3 ...
Anti-Human alpha2-Antiplasmin Purified (Polyclonal) (goat IgG)...
Anti (porcine) Vitronectin...
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Biology Products: